MedTrace Logo

Sickle Cell Disease: Targeting Alloantibody Formation Reduction; Risk Factors, and Genetics

NCT03288012 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2019-07-19

No results posted yet for this study

Summary

The focus of the study is the pathophysiological mechanism of allo-antibody formation after red blood cell transfusion in sickle cell disease patients.

Conditions

Sponsors & Collaborators

  • Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

    collaborator OTHER

  • Radboud University Medical Center

    collaborator OTHER

  • HagaZiekenhuis

    collaborator OTHER

  • Erasmus Medical Center

    collaborator OTHER

  • Sanquin Research & Blood Bank Divisions

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-09-20
Primary Completion
2021-06-01
Completion
2021-12-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03288012 on ClinicalTrials.gov